Thomsen LM. Patient safety in relation to biosimilars – how can we act as a patient organisation? EULAR 2017, OP0328-PARE.
RA-patiënt met kanker kan veilig worden behandeld met checkpointremmer
mei 2023 | Dermato-oncologie, Immuuntherapie, Longoncologie, RA